At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 490 enrolled

Drug / intervention

Escitalopram placebo +4 moredrug

Likely dose

Escitalopram 20 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00807248

NCT00807248Phase 2Completed

Compare CT.gov

Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder

H. Lundbeck A/S·interventional·Posted Dec 11, 2008·Updated Dec 17, 2012

In Brief

A Phase 2 clinical trial evaluating Escitalopram placebo, Gaboxadol placebo, and 3 other interventions for Major Depressive Disorder. Completed, enrolled 490 participants across 22 sites in 2 countries.

Detailed Summary

To compare the efficacy of escitalopram fixed dose 20 mg/day in combination with fixed doses of gaboxadol (5 and 10 mg/day) versus escitalopram fixed dose 20 mg/day after 8 weeks of treatment in patients with Major Depressive Disorder

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMajor Depressive Disorder

CountriesAustria, Russia

Collaborators--

Timeline

Phase 2CompletedFinished

200920102011201220132014201520162017201820192020202120222023202420252026

Enrollment StartNov 2008

First PostedDec 2008

Primary CompletionDec 2009

Study CompletionFeb 2010

TodayJul 2026

First PostedDec 11, 2008

Enrollment StartNov 1, 2008

Primary CompletionDec 1, 2009

Study CompletionFeb 1, 2010

TodayJul 2, 2026

Enrollment to primary: 1.1 yearsPosted 17.6 years ago